Lenalidomide Ratiopharm (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex, altering its activity. This triggers degradation of transcription factors Ikaros and Aiolos, which suppresses angiogenesis, modulates immune responses, and inhibits proliferation of malignant hematologic cells.

The specific dose and schedule of Lenalidomide Ratiopharm are determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Prescribers follow approved labeling and clinical guidelines to individualize therapy.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm. Women of childbearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may pass into milk and affect the infant.

To request Lenalidomide Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, sharing a similar mechanism with thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, while providing comparable efficacy. Pomalidomide is a newer IMiD used after lenalidomide failure, offering activity in some resistant cases.

Store Lenalidomide Ratiopharm tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lenalidomide Ratiopharm is taken orally as a tablet, usually once daily. It may be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any required dose adjustments.

The most serious adverse events include thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and the potential development of secondary primary malignancies. Patients should be monitored closely for these events throughout therapy.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal impairment or a history of thrombotic events.